Sanofi-Aventis and CureDM Group Holdings have entered a global license agreement on a novel human peptide, Pancreate, which could restore a patients’ ability to produce insulin and other pancreatic hormones in both type 1 and type 2 diabetes. Pancreate is a bioactive peptide sequence of a naturally occurring human protein that has been shown in preclinical studies to stimulate the growth of new insulin producing islets in the pancreas, resulting in restoration of normal metabolic function and...